Stockreport

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting [Seeking Alpha]

Omeros Corporation  (OMER) 
Last omeros corporation earnings: 3/2 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.omeros.com
PDF OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglobinuria with a differentiated mechanism, offering potential safety and dosing advantages over existing complement [Read more]